Journal of Clinical Oncology, Vol 16, 3662-3673, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer

JA Sloan, CL Loprinzi, SA Kuross, AW Miser, JR O'Fallon, MR Mahoney, IM Heid, ME Bretscher and NL Vaught
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.

PURPOSE: We report on a clinical trial developed to compare four different instruments that provide overall quality-of-life (QOL) scores, ranging from a simple, one-item instrument to more detailed instruments. Two issues addressed were (1) Will QOL tools suffer from missing data when used in a community-based cooperative group setting?, and (2) Are there additional data generated by a more detailed multiitem instrument over that provided by a single-item global QOL question? MATERIALS AND METHODS: A four-arm randomized trial was designed to compare four instruments that provide overall QOL scores in patients with advanced colorectal cancer. Patients and physicians completed the single-item Spitzer Uniscale (UNISCALE) at baseline and monthly. Patients were randomly assigned to complete, in addition, either the 22-item Functional Living Index-Cancer (FLIC), the five-item Spitzer QOL index (QLI), a picture-face scale (PICT), or nothing else. RESULTS: A total of 128 patients were randomized. Greater than 90% complete QOL data were obtained. There was strong correlation, concordance, and criterion-related validity among all four patient- completed tools. The UNISCALE had a greater decrease over time than did the FLIC (P=.005), which suggests a greater sensitivity; the UNISCALE was similar to the QLI and the PICT in this regard. Physicians provided lower UNISCALE scores than patients. Results supported the hypothesis that QOL is prognostic for survival. CONCLUSION: Patients can effectively complete QOL tools in a cooperative group setting with proper education of health care providers and patients. A simple single- item tool (UNISCALE) appears to be appropriate to obtain a measure of overall QOL.

This article has been cited by other articles:

				J. A. Martenson, M. Y. Halyard, J. A. Sloan, G. M. Proulx, R. C. Miller, R. L. Deming, S. J. Dick, H. A. Johnson, T.H. P. Tai, A. W. Zhu, et al. Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA J. Clin. Oncol., November 10, 2008; 26(32): 5248 - 5253. [Abstract] [Full Text] [PDF]

				C. M. Moinpour, K. A. Hayden, J. M. Unger, I. M. Thompson Jr, M. W. Redman, E. D. Canby-Hagino, B. A. Higgins, J. W. Sullivan, D. Lemmon, S. Breslin, et al. Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy J. Clin. Oncol., January 1, 2008; 26(1): 112 - 120. [Abstract] [Full Text] [PDF]

				C. M. Moinpour, G. W. Donaldson, and M. W. Redman Do General Dimensions of Quality of Life Add Clinical Value to Symptom Data? J Natl Cancer Inst Monographs, October 1, 2007; 2007(37): 31 - 38. [Abstract] [Full Text] [PDF]

				P. J. O'Dwyer, S. G. Eckhardt, D. G. Haller, J. Tepper, D. Ahnen, S. Hamilton, A. B. Benson III, M. Rothenberg, N. Petrelli, H.-J. Lenz, et al. Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups J. Clin. Oncol., June 1, 2007; 25(16): 2313 - 2321. [Abstract] [Full Text] [PDF]

				F. D. Wolinsky, F. W. Unverzagt, D. M. Smith, R. Jones, A. Stoddard, and S. L. Tennstedt The ACTIVE Cognitive Training Trial and Health-Related Quality of Life: Protection That Lasts for 5 Years J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2006; 61(12): 1324 - 1329. [Abstract] [Full Text] [PDF]

				F. D. Wolinsky, F. W. Unverzagt, D. M. Smith, R. Jones, E. Wright, and S. L. Tennstedt The Effects of the ACTIVE Cognitive Training Trial on Clinically Relevant Declines in Health-Related Quality of Life. J. Gerontol. B. Psychol. Sci. Soc. Sci., September 1, 2006; 61(5): S281 - S287. [Abstract] [Full Text] [PDF]

				F. Bonnetain, O. Bouche, P. Michel, C. Mariette, T. Conroy, D. Pezet, B. Roullet, J.-F. Seitz, B. Paillot, P. Arveux, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer Ann. Onc., May 1, 2006; 17(5): 827 - 834. [Abstract] [Full Text] [PDF]

				C. L. Loprinzi, R. Levitt, D. Barton, J. A. Sloan, S. R. Dakhil, D. A. Nikcevich, J. D. Bearden III, J. A. Mailliard, L. K. Tschetter, T. R. Fitch, et al. Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7 J. Clin. Oncol., March 20, 2006; 24(9): 1409 - 1414. [Abstract] [Full Text] [PDF]

				B. J. Monk, H. Q. Huang, D. Cella, and H. J. Long III Quality of Life Outcomes From a Randomized Phase III Trial of Cisplatin With or Without Topotecan in Advanced Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., July 20, 2005; 23(21): 4617 - 4625. [Abstract] [Full Text] [PDF]

				J. A. Meyerhardt, J. A. Sloan, D. J. Sargent, R. M. Goldberg, M. Pollak, R. F. Morton, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, and C. S. Fuchs Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1402 - 1410. [Abstract] [Full Text] [PDF]

				T. E. Witzig, P. T. Silberstein, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, J. A. Mailliard, K. M. Rowland, S. R. Alberts, J. E. Krook, R. Levitt, et al. Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy J. Clin. Oncol., April 20, 2005; 23(12): 2606 - 2617. [Abstract] [Full Text] [PDF]

				J. Bernhard Timing of quality of life assessment in cancer clinical trials: fine tuning remains a challenge Ann. Onc., April 1, 2005; 16(4): 523 - 524. [Full Text] [PDF]

				D. Provenzale and R. N. Gray Colorectal Cancer Screening and Treatment: Review of Outcomes Research J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 45 - 55. [Abstract] [Full Text] [PDF]

				A. Jatoi, K. Rowland, C. L. Loprinzi, J. A. Sloan, S. R. Dakhil, N. MacDonald, B. Gagnon, P. J. Novotny, J. A. Mailliard, T. I.L. Bushey, et al. An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort J. Clin. Oncol., June 15, 2004; 22(12): 2469 - 2476. [Abstract] [Full Text] [PDF]

				T. F. Kozelsky, G. E. Meyers, J. A. Sloan, T. G. Shanahan, S. J. Dick, R. L. Moore, G. P. Engeler, A. R. Frank, T. K. McKone, R. E. Urias, et al. Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy J. Clin. Oncol., May 1, 2003; 21(9): 1669 - 1674. [Abstract] [Full Text] [PDF]

				A. Jatoi, S. Kumar, J. A. Sloan, and P. L. Nguyen On Appetite and Its Loss J. Clin. Oncol., May 1, 2003; 21(90090): 79s - 81. [Full Text] [PDF]

				T. J. Hobday, J. W. Kugler, M. R. Mahoney, D. J. Sargent, J. A. Sloan, T. R. Fitch, J. E. Krook, M. J. O'Connell, J. A. Mailliard, M. T. Tirona, et al. Efficacy and Quality-of-Life Data Are Related in a Phase II Trial of Oral Chemotherapy in Previously Untreated Patients With Metastatic Colorectal Carcinoma J. Clin. Oncol., December 1, 2002; 20(23): 4574 - 4580. [Abstract] [Full Text] [PDF]

				A. Jatoi, H. E. Windschitl, C. L. Loprinzi, J. A. Sloan, S. R. Dakhil, J. A. Mailliard, S. Pundaleeka, C. G. Kardinal, T. R. Fitch, J. E. Krook, et al. Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study J. Clin. Oncol., January 15, 2002; 20(2): 567 - 573. [Abstract] [Full Text] [PDF]

				J. Sloan Asking the Obvious Questions Regarding Patient Burden J. Clin. Oncol., January 1, 2002; 20(1): 4 - 6. [Full Text] [PDF]

				J. Bernhard, R. Maibach, B. Thurlimann, C. Sessa, and M. S. Aapro Patients' Estimation of Overall Treatment Burden: Why Not Ask the Obvious? J. Clin. Oncol., January 1, 2002; 20(1): 65 - 72. [Abstract] [Full Text] [PDF]

				J. Addington-Hall and L. Kalra Measuring quality of life: Who should measure quality of life? BMJ, June 9, 2001; 322(7299): 1417 - 1420. [Full Text] [PDF]

				E. Simchen, N. Galai, D. Braun, Y. Zitser-Gurevich, E. Shabtai, and I. Naveh Sociodemographic and clinical factors associated with low quality of life one year after coronary bypass operations: The Israeli Coronary Artery Bypass Study (ISCAB) J. Thorac. Cardiovasc. Surg., May 1, 2001; 121(5): 909 - 919. [Abstract] [Full Text] [PDF]

				A. Jatoi, S. Kumar, J. A. Sloan, and P. L. Nguyen On Appetite and Its Loss J. Clin. Oncol., August 15, 2000; 18(15): 2930 - 2932. [Full Text] [PDF]

				D. Waldron, C. A. O'Boyle, M. Kearney, M. Moriarty, and D. Carney Quality-of-Life Measurement in Advanced Cancer: Assessing the Individual J. Clin. Oncol., November 1, 1999; 17(11): 3603 - 3611. [Abstract] [Full Text] [PDF]

				C. L. Loprinzi, J. W. Kugler, J. A. Sloan, J. A. Mailliard, J. E. Krook, M. B. Wilwerding, K. M. Rowland Jr, J. K. Camoriano, P. J. Novotny, and B. J. Christensen Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia J. Clin. Oncol., October 1, 1999; 17(10): 3299 - 3306. [Abstract] [Full Text] [PDF]

				M. R. Somerfield, J. Sloan, and C. Loprinzi Wherefore Global Quality-of-Life Assessment? J. Clin. Oncol., February 1, 1999; 17(2): 730 - 730. [Full Text] [PDF]